Diagnosis of thrombospondin type 1 domain-containing 7A (THSD7A)-associated membranous nephropathy
Direct Immunofluorescence (DIF)
RBTHSD7AIF
RBNEGTHSD7AIF
Thrombospondin
THSD7A-associated membranous nephropathy
Special
A preliminary pathology report is required for testing to be performed. Send information with specimen. The laboratory will not reject testing if a reason for testing is not provided; however appropriate testing and interpretation may be compromised or delayed. If not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.
Specimen Type: Kidney tissue
Preferred: 2 Unstained positively charged glass slide (25- x 75- x 1-mm) per test ordered; paraffin sections 3 to 4-microns thick
Acceptable: Formalin-fixed, paraffin-embedded (FFPE) kidney tissue block
If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.
See Specimen Required
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Special | Ambient (preferred) | ||
Frozen | |||
Refrigerated |
Diagnosis of thrombospondin type 1 domain-containing 7A (THSD7A)-associated membranous nephropathy
Thrombospondin type 1 domain-containing 7A (THSD7A) is a target antigen in membranous nephropathy (MN) and is detected in approximately 3% to 5% of non- phospholipase A2 receptor (PLA2R)-associated MN patients. Differentiating THSD7A-associated MN from PLA2R-associated MN is critical as approximately 20% of patients with THSD7A-associated MN have solid malignancy suggesting that THSD7A-associated MN is more likely to be secondary to malignancy than PLA2R-associated MN.
Staining is interpreted and reported as negative or positive.
No significant cautionary statements
1. Hoxha E, Beck Jr LH, Wiech T et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol. 2017;28:520-531
2. Larsen CP, Cossey LN, Bech LH. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. Mod Pathol. 2016;29:421-426
3. Sharma SG, Larsen CP: Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. Mod Pathol. 2018;31(4):616-622
Direct immunofluorescence staining on sections of formalin-fixed, paraffin-embedded kidney tissue.(Unpublished Mayo method)
Monday through Friday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
88346-Primary IF
88350-If additional IF
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
THSIF | THSD7A Immunofluorescence | 101116-2 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
605245 | Interpretation | 50595-8 |
606383 | Participated in the Interpretation | No LOINC Needed |
606384 | Report electronically signed by | 19139-5 |
606385 | Addendum | 35265-8 |
606386 | Gross Description | 22634-0 |
606387 | Material Received | 22633-2 |
606388 | Disclaimer | 62364-5 |
606389 | Case Number | 80398-1 |